Interview: Fernand Labrie – President and CEO, Endoceutics

Dr. Fernand Labrie shares the significant achievements of Endoceutics, in launching its first breakthrough product for post-menopausal vulvar and vaginal atrophy, known as the ‘female Viagra’, the innovations behind the specialty area of ‘intracrinology’ that he discovered, and his perspective on the importance of homegrown innovation for Canada’s development. Having met with you four years ago, what have been some of the major changes for Endoceutics since?
"Intracrinology is a newly established field within women’s health. There is definitely a huge and pressing unmet medical need here. To give an indication, in the US, 32 million women suffer from vaginal atrophy symptoms like dryness and pain during sexual activity. Yet only one million currently receive treatment – less than 3 percent."
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report